Fig. 5 | Scientific Reports

Fig. 5

From: Erdafitinib suppresses pathological retinal angiogenesis via dual targeting of FGFR and VEGFR2 signaling

Fig. 5

Erdafitinib exerts inhibitory effects on relative protein expression without significantly impacting cell viability. (A, B) Protein expression levels of AKT, ERK, P-AKT, P-ERK, P-VEGFR2, and VEGFR2 were examined through Western blot analysis (n = 6 replicates). (C–F) The impact of Erdafitinib on the expression of pathway proteins P-AKT, P-VEGFR2, P-ERK1, and P-ERK2 was observed, all of which were inhibited. (n = 3 blots). (G) Cell viability (n = 12 wells/group) assessment revealed that Erdafitinib (at concentrations of 2µM and 4µM) did not exhibit notable cytotoxicity after 24 h (p < 0.05). All individual experiments were performed at least thrice. Data are presented as mean ± S.E.M. Results were quantified and displayed in bar graph format, with p < 0.001 indicating a significant difference compared to the control group.

Back to article page